Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice.

Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice.

Item
http://www.wikidata.org/entity/Q38894035
Inhibition of Thrombin With PPACK-Nanoparticles Restores Disrupted Endothelial Barriers and Attenuates Thrombotic Risk in Experimental AtherosclerosisAnti-inflammatory effect of factor-Xa inhibitors in Japanese patients with atrial fibrillation.Rivaroxaban improves patency and decreases inflammation in a mouse model of catheter thrombosis.Direct oral anticoagulants: an alternative treatment for thrombotic antiphospholipid syndrome?Activated Factor X Induces Endothelial Cell Senescence Through IGFBP-5Protease-Activated Receptor-2 Deficiency Attenuates Atherosclerotic Lesion Progression and Instability in Apolipoprotein E-Deficient Mice.Local Production of Activated Factor X in Atherosclerotic Plaque Induced Vascular Smooth Muscle Cell Senescence.Rationale and design of a randomized trial of apixaban vs warfarin to evaluate atherosclerotic calcification and vulnerable plaque progression.Effects of rivaroxaban on intimal hyperplasia and smooth muscle cell proliferation at the carotid artery anastomosis site in rabbits.Effects on bone metabolism markers and arterial stiffness by switching to rivaroxaban from warfarin in patients with atrial fibrillation.FXa inhibition by rivaroxaban modifies mechanisms associated with the pathogenesis of human abdominal aortic aneurysms.Reduction of intracerebral hemorrhage by rivaroxaban after tPA thrombolysis is associated with downregulation of PAR-1 and PAR-2.Dual Anticoagulant and Antiplatelet Therapy for Coronary Artery Disease and Peripheral Artery Disease Patients.Intake of Vitamin K Antagonists and Worsening of Cardiac and Vascular Disease: Results From the Population-Based Gutenberg Health StudyDirect factor Xa inhibition attenuates acute lung injury progression via modulation of the PAR-2/NF-κB signaling pathway
P2860

Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice.

Item
http://www.wikidata.org/entity/Q38894035
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Rivaroxaban, a novel oral anti ...... zation in ApoE-deficient mice.
@en
type
label
Rivaroxaban, a novel oral anti ...... zation in ApoE-deficient mice.
@en
prefLabel
Rivaroxaban, a novel oral anti ...... zation in ApoE-deficient mice.
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Rivaroxaban, a novel oral anti ...... ization in ApoE-deficient mice
@en
P2093
P304
P31
P356
10.1016/J.ATHEROSCLEROSIS.2015.03.023
P433
P478
P50
P577
P698
P921